Loading…
← CockpitCompetitor Analysis › 600739.SS Liaoning Cheng Da Co., Ltd. Class AOpen in the cockpit ↗

Liaoning Cheng Da Co., Ltd. Class A600739.SSCompetitor analysis, valuation and peers

China · CNY·Industrials›Air Freight/Couriers

Dalian-based state-controlled group with a human-vaccine maker, pharmacy chain, commodity trading and a stake in GF Securities.

Momentum strong 75
Mkt cap
$2.21B
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$15.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-8.9 pp
WACC 7.0%
Hurdle
+14 pp
Req g minus delivered
Close · CNYCN¥9.70
1D-0.8%
1W-1.9%
1M-2.5%
3M-9.8%
6M-14.5%
YTD-13.2%
1Y-23.1%
ATR %1.9%
52w lowhigh25.8% off high

What Liaoning Cheng Da does

Dalian-based state-controlled group with a human-vaccine maker, pharmacy chain, commodity trading and a stake in GF Securities.

Profit rests on three legs: human vaccines made by listed subsidiary Chengda Biotech (rabies and Japanese encephalitis), equity income from its associate stake in GF Securities, and commodity and textile trading plus a pharmacy and wholesale unit. Results swing with securities-market conditions and vaccine demand.

Products and services

  • Human rabies vaccine (Chengda Biotech)
  • Japanese encephalitis vaccine
  • Pharmacy retail and wholesale (Cheng Da Fangyuan)
  • Textile and bulk commodity trading
  • Equity stake in GF Securities

Customers

  • Disease-control centres and vaccination clinics
  • Pharmacy shoppers and hospitals
  • Commodity and textile trading counterparties

Where it sits in the supply chain

  • Conglomerate
  • Vaccines, trading and financial…
  • Human vaccines, pharmacy retail…

What could go right

  • Earnings from its GF Securities stake
  • Vaccine volumes recovering

What could go wrong

  • Commodity-price swings in trading
  • Vaccine pricing and demand in China

Moat: narrow (regulatory licence, process know-how). Vaccine licences and production know-how at Chengda Biotech; trading and pharmacy units have little edge.

Headquarters: Dalian, China · Founded: 1993 · Employees: 2,740

Named competitors

Liaoning Cheng Da at a glance

Size Liaoning Cheng Da (600739.SS) is a China Industrials company (Air Freight/Couriers) with a market value of $2.21B, the 1085th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.70 on 18 Nov 2026.

Performance Over six months the shares fell 14.5%, against -9.0% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 26.6% over the last twelve months (peer median +7.5%); the operating margin is -16.6% (peer median 4.4%).

Valuation It trades at 3.0× enterprise value to sales against a peer median of 1.2× (2nd most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.9 points below its cost of capital (7.0% WACC).

Relative performance

85909510021 May 202621 Aug 202618 Nov 2026Peer median 91600739.SS 86
Six months, rebased to 100: Liaoning Cheng Da against the median of its 20 peers (local-currency closes).

Liaoning Cheng Da financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥8.17BCN¥9.89BCN¥10.8BCN¥10.7BCN¥14.6B
Revenue growth—-8%0%-26%—
Gross profitCN¥1.45BCN¥1.12BCN¥1.36BCN¥1.68BCN¥2.55B
EBITDAn/a-CN¥288MCN¥375MCN¥263MCN¥1.58B
Net incomeCN¥1.57BCN¥737MCN¥210MCN¥233MCN¥1.22B
Free cash flowCN¥1.30BCN¥696MCN¥730M-CN¥56.1MCN¥1.56B
Capital expenditureCN¥203MCN¥341MCN¥455MCN¥703MCN¥647M
Total debtCN¥14.9BCN¥15.1BCN¥14.3BCN¥14.0BCN¥14.6B

Quarterly statements and history in the cockpit →

Liaoning Cheng Da competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-10%0%+10%00121390696038710021209301600755IDL9075AEGISVOPAK600575HUBG600787600153002183DELHIVERY6001790517BONHRSCI600739.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Liaoning Cheng Da is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×20×00121390696038710021209301600755IDLAEGISVOPAK600575600787002183DELHIVERYSCI600739.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Liaoning Cheng Da is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%0012139069603871002120IDL90756001530021836001790517BONHR603565600739.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Liaoning Cheng Da is the large dot.

Liaoning Cheng Da competitors and peer comparison

Head to head with its named competitors (600739.SS vs 300122.SZ vs 300142.SZ vs 688276.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Liaoning Cheng Da 600739.SS$2.21B-15%-27%-17%3.0×4.0%
Chongqing Zhifei Biological Products 300122.SZ$5.28B-1%-28%-210%5.3×-6.5%
Walvax Biotechnology 300142.SZ$2.48B-26%-23%5%9.4×29.5%
Changchun BCHT Biotechnology 688276.SS$992M-2%+2%-29%9.9×n/a
Hualan Biological Engineering 002007.SZ$3.20B-17%-11%17%5.3×15.8%
Yifeng Pharmacy Chain 603939.SS$4.84B+16%+5%10%1.3×-9.3%

How Liaoning Cheng Da compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Liaoning Cheng Da against its 20 peers (data as of 18 Nov 2026)
Measure600739.SSPeer medianRank in peer set
1-month return-2.5%-1.3%8th lowest of 21
6-month return-14.5%-9.0%7th lowest of 21
Distance from 52-week high-25.8%-24.3%10th lowest of 21
Revenue growth (TTM)-26.6%+7.5%lowest of 20
Operating margin-16.6%4.4%lowest of 19
EV / Sales3.0×1.2×2nd most expensive of 20
Growth the price implies (Req g, 7 yrs)4.0%3.2%7th least demanding of 13
Growth delivered (Del g)-10.1%+9.1%lowest of 13
Hurdle (Req g minus delivered)+14.1 pp-6.3 pp2nd most demanding of 13
ROIC minus cost of capital-8.9 pp-2.7 pp3rd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Liaoning Cheng Da 600739.SSChina$2.21B-15%-27%-17%3.0×4.0%-10.1%
China Railway Special Cargo Logistics 001213.SZChina$2.29B-12%-3%3%1.2×1.7%+7.2%
SENKO 9069.TJapan$2.52B+18%+10%4%0.8×4.4%+9.5%
Jiayou International Logistics 603871.SSChina$2.53B+1%-10%19%1.9×-6.9%+20.7%
Yunda 002120.SZChina$2.67B-18%+7%4%0.3×-13.5%+9.0%
Mitsubishi Logistics 9301.TJapan$2.74B-11%-1%6%1.8×n/an/a
Xiamen International Trade 600755.SSChina$1.77B-10%+28%0%0.2×n/an/a
ID Logistics IDL.PAFrance$2.76B+5%+16%4%1.0×10.6%+17.9%
Fukuyama Transporting 9075.TJapan$1.60B+12%+7%4%1.0×11.0%+2.2%
Aegis Vopak Terminals AEGISVOPAK.NSIndia$3.32B+41%+17%53%37.0×n/an/a
Huaihe Energy 600575.SSChina$3.33B-15%+38%n/a1.2×n/an/a
Hub HUBGUnited States$1.44B-42%n/an/an/an/an/a
CMST Development 600787.SSChina$1.44B-10%+23%0%0.1×n/an/a
Xiamen C&D 600153.SSChina$3.53B-19%-6%1%0.5×21.1%+9.3%
Eternal Asia Supply Chain Management 002183.SZChina$1.38B-49%-25%0%0.6×29.4%0.0%
Delhivery DELHIVERY.NSIndia$3.61B-2%+24%0%2.8×n/an/a
Antong 600179.SSChina$3.66B-8%+9%16%2.0×-4.7%+13.5%
COSCO SHIPPING International (Hong Kong) 0517.HKHong Kong$1.28B+10%+1%5%1.1×1.9%+1.5%
Bonheur BONHR.OLNorway$1.28B+11%0%5%1.5×9.5%+18.0%
Shipping Corporation of India SCI.NSIndia$1.28B-24%+37%27%1.9×n/an/a
Shanghai Zhonggu Logistics 603565.SSChina$3.98B+18%+4%27%2.1×-14.3%+0.4%

Questions

Who are Liaoning Cheng Da's main competitors?
Named competitors: Chongqing Zhifei Biological (300122.SZ), Walvax Biotechnology (300142.SZ), Changchun BCHT Biotechnology (688276.SS), Hualan Biological Engineering (002007.SZ), Yifeng Pharmacy Chain (603939.SS). The cockpit's measured peer set (industry) also includes China Railway Special Cargo Logistics (001213.SZ), SENKO (9069.T), Jiayou International Logistics (603871.SS), Yunda (002120.SZ), Mitsubishi Logistics (9301.T), Xiamen International Trade (600755.SS).
Is Liaoning Cheng Da expensive compared with its peers?
On ev / sales it trades at 3.0× against a peer median of 1.2×, 2nd most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Liaoning Cheng Da stock performed?
Over six months to 18 Nov 2026 the shares returned -14.5% against -9.0% for the median peer; over one year -23.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.